SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : AMD, ARMH, INTC, NVDA -- Ignore unavailable to you. Want to Upgrade?


To: Vattila who wrote (35848)3/12/2020 4:24:11 PM
From: THE WATSONYOUTHRespond to of 73046
 
........be aware that the hot spot in New Rochelle NY originated from a one person source and is now responsible (tracing) for about 120 of the cases in NY.............given that degree of spread, it did not take a large number of infected individuals entering the country in Jan to produce the current state of affairs. Many thousands of Chinese nationals or Americans returned from China in the Jan. time frame. In addition, Milan Italy is the industrial hub of Italy with a large China/Milan human transfer. Obviously, the Chinese have a large influence in Iran as well.



To: Vattila who wrote (35848)3/12/2020 4:32:24 PM
From: THE WATSONYOUTHRead Replies (2) | Respond to of 73046
 
....these people are currently being tested in NY....they can not now do random testing

The testing priorities include:

A person who has come within proximate contact (same classroom, office, or gatherings) of another person known to be positive.
A person who has traveled to a country that the CDC has issued a Level 2 or Level 3 Travel Health Notice, and shows symptoms of illness. On Monday, Level 3 notices covered China, South Korea, Italy and Iran. Level 2 notices covered Japan.
A person who is quarantined (mandatory or precautionary) and has shown symptoms of COVID-19 illness.
A person who is symptomatic and has not tested positive for any other infection.
Other cases where the facts and circumstances warrant as determined by the treating clinician in consultation with state and local department of health officials.